atenolol has been researched along with harmine in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Colau, D; Dolusić, E; Frédérick, R; Larrieu, P; Masereel, B; Moineaux, L; Pilotte, L; Pochet, L; Stroobant, V; Van den Eynde, B; Wouters, J | 1 |
| Chen, H; Ding, H; Gao, Y; Jiang, X; Liu, W; Liu, X; Tian, L; Xu, Z; Zhao, Q | 1 |
| Abourashed, EA; Khan, IA; Khan, SI; Walker, LA | 1 |
3 other study(ies) available for atenolol and harmine
| Article | Year |
|---|---|
Tryptophan 2,3-dioxygenase (TDO) inhibitors. 3-(2-(pyridyl)ethenyl)indoles as potential anticancer immunomodulators.
Topics: Animals; Antineoplastic Agents; Biological Availability; Cell Line; Drug Design; Enzyme Inhibitors; Humans; Immunologic Factors; Indoles; Kinetics; Mice; Neoplasms; Structure-Activity Relationship; Tryptophan Oxygenase | 2011 |
Design, synthesis and biological evaluation of harmine derivatives as potent GSK-3β/DYRK1A dual inhibitors for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Cell Line; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Dyrk Kinases; Glycogen Synthase Kinase 3 beta; Harmine; Humans; Models, Molecular; Molecular Structure; Neuroprotective Agents; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Structure-Activity Relationship | 2021 |
Transport of harman alkaloids across Caco-2 cell monolayers.
Topics: Adrenergic alpha-Antagonists; Algorithms; Alkaloids; Atenolol; Biological Transport, Active; Caco-2 Cells; Chromatography, High Pressure Liquid; Fluoresceins; Fluorescent Dyes; Harmine; Humans | 2004 |